Skip to content

Kyverna Therapeutics, Inc. KYTX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$10.25M-26.0%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$46.78M-11.3%
Vor Biopharma logo
Vor BiopharmaVOR
$2.94M-90.5%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$81.05M-8.9%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.38M+29.5%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$1.04M-2.0%

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$498.52M+276%
Enterprise value$475.49M+475%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s operating lease liabilities (total)?
Kyverna Therapeutics, Inc. (KYTX) reported operating lease liabilities (total) of $8.72M in Q1 2026.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.